New data from two phase II studies from two companies showed progress in their respective Parkinson’s disease programs. The data for both therapies, from Anavex Life Sciences Corp. and Sage Therapeutics Inc., were presented on opening day, March 15, at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held in Barcelona until March 20.
Neuton Health Co. Ltd.’s virtual reality (VR)-based therapy for acrophobia has been given class II medical device approval from China’s NMPA. The VR therapy, known as Specific Fear Rehabilitation Training Software, was co-developed with the Shanghai Mental Health Center. The digital therapy company said it is the first VR device of its kind for a specific phobia approved in the world.
The discovery of increased levels of dopamine in the basolateral amygdala of the brain at the transition from non-rapid eye movement (NREM) to REM sleep in mice suggests a druggable sleep disorder target, according to a Japanese study.
Developed by Infrascan Inc., the FDA-cleared Infrascanner device was touted as the first hand-held device to help detect bleeding in the skull and supported financially by the U.S. military anxious to treat moderate to severe traumatic brain injury in wounded service members. The FDA has now expanded the Infrascanner’s use to traumatic intracranial hematomas or brain bleeds in pediatric patients aged 2 years and older.
RSS
